IRulya Therapeutics Inc. (IRLA) Income Statement
IRLA 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIRLA revenue and net income
IRLA growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IRLA quarterly EPS vs estimates
IRulya Therapeutics beat the analyst EPS estimate in 2 of the last 4 quarters. Next report: November 11, 2026 (estimate $-0.83).
IRLA income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $142,000 | — | — | — |
| Gross profit | −$142,000 | — | — | — |
| Research & development | $35.4M | $18.6M | $9.4M | $25.2M |
| Sales, general & admin | $15.0M | $17.6M | $17.7M | $26.0M |
| Total operating expenses | $50.3M | $57.3M | $34.6M | $52.0M |
| Operating income | −$50.4M | −$57.3M | −$34.6M | −$52.0M |
| Interest income | $1.2M | $2.9M | $3.5M | $1.1M |
| Interest expense | — | — | — | $568,000 |
| Income before taxes | −$80.8M | −$56.7M | −$31.6M | −$51.9M |
| Income taxes | $3.2M | $87,000 | −$197,000 | −$284,000 |
| Net income | −$84.0M | −$56.8M | −$31.4M | −$51.7M |
| EBITDA | −$80.6M | −$36.0M | −$26.8M | −$51.0M |
| EPS (diluted) | −$339.16 | −$387.98 | — | −$320.78 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $36,000 | — | — | — |
| Gross profit | — | −$36,000 | — | — | — |
| Research & development | $5.5M | $6.8M | $12.6M | $8.1M | $6.6M |
| Sales, general & admin | $16.6M | $4.3M | $3.6M | $3.3M | $3.3M |
| Total operating expenses | $79.8M | $11.1M | $16.2M | $13.4M | $9.9M |
| Operating income | −$79.8M | −$11.1M | −$16.2M | −$13.4M | −$9.9M |
| Interest income | $584,000 | $160,000 | $227,000 | $300,000 | $311,000 |
| Income before taxes | −$75.4M | $30.6M | −$36.3M | −$13.5M | −$16.0M |
| Income taxes | $75,000 | −$5.3M | — | −$46,000 | — |
| Net income | −$75.5M | $35.9M | −$39.5M | −$13.4M | −$16.0M |
| EBITDA | −$75.4M | $30.6M | −$16.2M | −$11.3M | −$9.9M |
| EPS (diluted) | −$12.15 | $57.60 | −$152.00 | −$50.00 | −$68.75 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IRLA's financial statements (latest annual report filed April 10, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IRLA financial results
IRulya Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $84.0 million. Diluted earnings per share came to −$339.16.
See the IRLA stock overview for the latest quote and news, or the IRLA chart for price history and technical indicators.
IRLA income statement FAQ
Does IRulya Therapeutics have revenue?
IRulya Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is IRulya Therapeutics profitable?
No. IRulya Therapeutics reported a net loss of $84.0 million in fiscal 2025.
How much does IRulya Therapeutics spend on research and development?
IRulya Therapeutics spent $35.4 million on research and development in fiscal 2025.
What are IRulya Therapeutics's earnings per share?
IRulya Therapeutics earned $-339.16 per diluted share in fiscal 2025, compared with $-387.98 a year earlier.
When will IRulya Therapeutics report its next earnings?
IRulya Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does IRulya Therapeutics's fiscal year end?
IRulya Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 10, 2026.